How has Indian Pharma responded to the challenges brought on by the Covid19 crisis and the inability to connect with doctors and other Rx influencers?
Is it back to business-as-usual or have some companies learned from their mistakes and become digital/hybrid savvy?
How will Indian Pharma cope with the possibility of another lockdown and F2F meeting restrictions in view of the rising Omicron wave?
Take a look at our survey results and tell us what has changed since 2020?
Infographic overview of the MedicinMan Survey in partnership with CredoWeb
Smaller Indian pharma companies with less than a 100 MSRs and less than Rs.100 Cr. turnover were the most highly impacted from the COVID-19 pandemic.
That can be explained by the fact that contact with local doctors was their only channel of communication and it was shut as India was one of the first countries to go into a lockdown in March 2020.
As a whole, Indian domestic companies saw greater impact on their revenues compared to MNCs. The biggest reasons for revenue impact turn out to be lack of customer engagement and supply chain issues.
These are some of the conclusions in a national survey conducted by MedicinMan.
